Rich Countries Pre-Purchasing Coronavirus Vaccines, Potentially Leaving Poorer Nations Without, Duke Analysis Shows; Media Outlets Report On Other Vaccine, Therapeutic News

Washington Post: As rich countries hoard potential coronavirus vaccine doses, rest of world could go without
“Rich countries have already snapped up billions of doses of potential coronavirus vaccines, potentially leaving poor countries without enough supply for years to come, a new study shows. An analysis from researchers at Duke University’s Global Health Innovation Center, found that high- and middle-income countries have already purchased 3.8 billion doses, with options for 5 billion more. As a result, relatively wealthy nations will likely be able to vaccinate their entire populations, with billions of others relegated to the back of the line. People in low-income countries could be waiting until 2024…” (Rauhala, 11/2).

AP: South African firm and Johnson & Johnson strike vaccine deal (Magome, 11/2).

Bloomberg: China’s Race for First Covid-19 Vaccine Raises Safety Questions (O’Brien, 11/2).

Financial Times: Race to discover pandemic vaccine faces hurdles (Jack, 11/2).

The Guardian: Covid-19: How do you make a vaccine? — podcast (Finlay/Waters, 11/3).

STAT: Gilead faces pressure to relinquish valuable FDA voucher awarded with remdesivir approval (Silverman, 11/2).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.